ArticleIndian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine2025
Health Technology Assessment in the Early Phases of Development of Medical Devices: A Catalyst for Sustainable Growth and Innovation.
Article in Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
India's medical device sector is experiencing growth and technological advancements, driven by increased interest and government support in research and development. To promote innovation, significant amount of time and resources are spent on research and development before realization of a final product. To optimize the judicious allocation of these limited resources, the implementation of Health Technology Assessment (HTA) during the early phases of product development and testing should be adopted. Conducting early HTA enables an innovator to make well-informed decisions, demonstrate value to stakeholders, and improve market access by determining an appropriate price for the device which represents its value. The health economic models can be used throughout the life cycle of the innovation to inform decision making; however, the challenge lies in the lack of awareness regarding early HTA. It is thus imperative to increase knowledge and build capacity of the researchers, and foster collaboration between innovators and government organizations to realize the true potential of early HTA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.